Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study

被引:0
|
作者
Guo, Weijian
Bi, Feng
Dong, Jian
Jin, Chuan
Niu, Zuoxing
Wang, Yusheng
Sun, Meili
Wang, Teng
Yu, Dajun
He, Yifu
Zhang, Ruixing
Yin, Xianli
Feng, Wenlei
Zhang, Meijiang
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Gastrointestinal Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, Dept Abdominal Oncol, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
[4] Guangzhou Med Univ, Affiliated Tumor Hosp, Guangzhou, Peoples R China
[5] Shandong Canc Hosp, Jinan, Peoples R China
[6] Shanxi Canc Hosp, Taiyuan, Peoples R China
[7] Shandong First Med Univ, Dept Oncol, Cental Hosp, Dept Oncol, Jinan, Peoples R China
[8] Jiangnan Univ, Affiliated Hosp, Dept Oncol, Wuxi Peoples Hosp 4, Wuxi, Jiangsu, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Surg Oncol, Bengbu, Peoples R China
[10] Anhui Prov Canc Hosp, Hefei, Peoples R China
[11] Hebei Med Univ, Hebei Canc Hosp, Hosp 4, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China
[12] Hunan Canc Hosp, Changsha, Peoples R China
[13] Qilu Pharmaceut Co Ltd, Dept Oncol, Jinan, Peoples R China
[14] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Peoples R China
[15] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Shandong, Peoples R China
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
3578
引用
收藏
页数:1
相关论文
共 50 条
  • [1] A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
    Guo, W.
    Bi, F.
    Dong, J.
    Jin, C.
    Niu, Z.
    Wang, Y.
    Sun, M.
    Wang, T.
    Yu, D.
    He, Y.
    Zhang, R.
    Yin, X.
    Feng, W.
    Zhang, M.
    Li, L.
    Zhang, B.
    Kang, X.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1511 - S1511
  • [2] Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
    Feng Bi
    Jian Dong
    Chuan Jin
    Zuoxing Niu
    Wenhui Yang
    Yifu He
    Dajun Yu
    Meili Sun
    Teng Wang
    Xianli Yin
    Ruixing Zhang
    Kehe Chen
    Keming Wang
    Zhiwu Wang
    Wei Li
    Zhongtao Zhang
    Hangyu Zhang
    Qunyi Guo
    Xin Wang
    Lei Han
    Xizhi Zhang
    Wei Shen
    Liangming Zhang
    Jieer Ying
    Miao Wu
    Weiguo Hu
    Zeng Li
    Xiaofen Li
    Wenlei Feng
    Baihui Zhang
    Lingyan Li
    Xiaoyan Kang
    Weijian Guo
    [J]. Journal of Hematology & Oncology, 17 (1)
  • [3] Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
    Lorenzi, Maria
    Amonkar, Mayur
    Zhang, Jacky
    Mehta, Shivani
    Liaw, Kai-Li
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [4] STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS
    Lorenzi, M.
    Amonkar, M.
    Zhang, J.
    Mehta, S.
    Liaw, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S22 - S23
  • [5] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
    Maio, M.
    Ascierto, P. A.
    Motola Kuba, D.
    Penel, N.
    Cassier, P. A.
    Bariani, G. M.
    De Jesus-Acosta, A.
    Doi, T.
    Longo Munoz, F.
    Miller, W. H.
    Oh, D-Y.
    Gottfried, M.
    Yao, L.
    Jin, F. J.
    Gozman, A.
    Marabelle, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S590
  • [7] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
    Li, J.
    Xu, Y.
    Zang, A.
    Gao, Y.
    Gao, Q.
    Zhang, Y.
    Wang, D.
    Xu, J.
    Yuan, Y.
    Jiang, H.
    Ying, J.
    Shi, C.
    Deng, Y.
    Wang, J.
    Liu, T.
    Huang, Y.
    Shi, M.
    Wang, K.
    Hu, H.
    Shen, L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S640 - S640
  • [9] MyTACTIC: Afficacy and safety of atezolizumab (atezo) plus chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)
    Spigel, David R.
    Hussein, Maen A.
    Zuniga, Richard
    Mahadevan, Daruka
    Winn, Robert
    Darbonne, Walter C.
    Yoo, Bongin
    Kim, Young
    Whitehead, Zach
    Vanderwalde, Ari M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
    Chase, M.
    Vasudevan, A.
    Amonkar, M.
    Myer, N.
    Wang, T.
    Prabhu, V
    Turzhitsky, V
    Spira, A.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S452 - S452